Shenzhen Salubris Pharmaceuticals Co Ltd

On the evening of October 8, several A-share listed companies disclosed progress on share buybacks, with Midea Group having repurchased nearly 10 billion yuan and planning to cancel all repurchased shares. Midea Group's announcement showed that as of September 30, the company had repurchased 123 million A-shares through centralized bidding, accounting for 1.61% of its current total share capital, with the highest transaction price at 87.71 yuan per share and the lowest at 73.66 yuan per share, for a total payment of 9.94 billion yuan, excluding transaction fees. The buyback plan originally set a repurchase amount of no more than 13 billion yuan and no less than 6.5 billion yuan, with a repurchase price not exceeding 100 yuan per share. After board review, the use of repurchased shares was changed from equity incentive plans and employee stock ownership plans to cancellation to reduce registered capital. On the same day, CATL disclosed that it had repurchased 10.9452 million A-shares, accounting for 0.2482% of total share capital, with a total transaction amount of 3.303 billion yuan. Its buyback plan proposes to use no less than 20 billion yuan and no more than 40 billion yuan, and the repurchased shares will also be cancelled to reduce registered capital. In addition, GigaDevice repurchased 2.4519 million shares, paying 948 million yuan; Salubris repurchased 8.3196 million shares, with a total transaction amount of 266 million yuan; Jianlong Weina repurchased 1.0002 million shares, paying a total of 26.4348 million yuan; YTO Express repurchased 2.2933 million shares, with a cumulative repurchase amount of 39.9847 million yuan.

Salubris disclosed that as of September 30, 2026, the company had repurchased 8.32 million shares, accounting for 0.75% of total share capital, with repurchase transaction prices ranging from 29.28 yuan to 40.8 yuan per share, and total repurchase funds paid amounting to 266 million yuan. In the first half of 2026, Salubris achieved revenue of 2.479 billion yuan and net profit attributable to the parent of 387 million yuan.

Salubris announced that the clinical trial application for its self-developed innovative drug SAL012 for injection has been accepted by the National Medical Products Administration for the treatment of advanced solid tumors. The application was jointly submitted by Salubris and its wholly-owned subsidiaries Salubris Chengdu Biologics and Salubris Suzhou Pharmaceutical. In the first quarter of 2026, Salubris achieved revenue of 1.228 billion yuan and net profit attributable to the parent of 225 million yuan.